Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases

BACKGROUND: Recent studies have suggested obesity could contribute to improved outcomes of immune checkpoint inhibitor (ICI)-based treatment. Non-alcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease, is also obesity-related, but its association with the efficacy of IC...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Transl Lung Cancer Res
Egile Nagusiak: Zhou, Juan, Zhou, Fei, Chu, Xiangling, Zhao, Jing, Wu, Yan, Zhao, Wencheng, Xu, Chuan, Su, Chunxia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225134/
https://ncbi.nlm.nih.gov/pubmed/32420071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2020.04.15
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak